Cutaquig

Cutaquig is a brand name for a human immunoglobulin (IgG) used for subcutaneous administration. It is primarily indicated for the treatment of primary immunodeficiency (PI) in adults. Cutaquig is produced by Octapharma, a global healthcare company specializing in the development and production of human proteins from human plasma and human cell lines.

Composition and Formulation

Cutaquig is a solution of human immunoglobulin G (IgG) with a concentration of 16.5%. It is derived from human plasma and contains a broad spectrum of IgG antibodies. The formulation is designed for subcutaneous injection, allowing for self-administration by patients.

Indications

Cutaquig is indicated for the treatment of primary immunodeficiency (PI) in adults. Primary immunodeficiency encompasses a group of disorders where part of the body's immune system is missing or does not function properly. This can lead to increased susceptibility to infections.

Administration

Cutaquig is administered subcutaneously, which means it is injected into the fatty tissue just under the skin. This method of administration allows for a more consistent absorption of the immunoglobulin and can be done by the patient at home after proper training by a healthcare professional.

Mechanism of Action

The primary mechanism of action of Cutaquig involves the replacement of missing or deficient IgG antibodies in patients with primary immunodeficiency. By providing these antibodies, Cutaquig helps to enhance the immune response and reduce the frequency and severity of infections.

Side Effects

Common side effects of Cutaquig include local reactions at the injection site, such as redness, swelling, and itching. Systemic side effects may include headache, fatigue, fever, and nausea. Serious side effects are rare but can include severe allergic reactions and thromboembolic events.

Storage and Handling

Cutaquig should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). It should not be frozen. Before administration, the solution should be brought to room temperature. Any unused product or waste material should be disposed of in accordance with local requirements.

Related Pages

• Primary immunodeficiency
• Immunoglobulin therapy
• Subcutaneous injection
• Octapharma

See Also

• Immune system
• Antibody
• Plasma (blood)
• Healthcare